References to accompany the December 2016 issue of Kai Tiaki Nursing New Zealand

1. Howell, J. et al. (2016). The increasing burden of potentially preventable liver disease among adult liver transplant recipients: A comparative analysis of liver transplant indication by era in Australia and New Zealand. Journal of Gastroenterology and Hepatology. 31(2): 434-441.
2. Williams, R. et al. (2014). Addressing liver disease in the UK: a blueprint for arraigning excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity and viral hepatitis. The Lancet. 384(9958): 1953-1997.
3. Coppell, K. et al. (2015). Obesity and the extent of lover damage among adult New Zealanders: findings from a national survey. Obesity Science and Practice. Accessed November 2016. http://onlinelibrary.wiley.com/store/10.1002/osp4.13/asset/osp413.pdf?v=1&t=ivip9x7w&s=ebf23ee03b35e40fb37e4fe60d37e1b4d374e6ff&systemMessage=Wiley+Online+Library+will+be+unavailable+on+Saturday+26th+November+2016+from+07%3A00-11%3A00+GMT+%2F+02%3A00-06%3A00+EST+%2F+15%3A00-19%3A00+SGT+for+essential+maintenance.++Apologies+for+the+inconvenience.
4. NICE (2016a). Non-alcoholic fatty liver disease (NAFLD): assessment and management. Accessed November 2016. www.nice.org.uk/guidance/ng49
5. The Lancet (2014). UK liver disease crisis. The Lancet Commissions. Accessed November 2016. http://www.thelancet.com/pb/assets/raw/Lancet/stories/commissions/lancet-liver-disease-infographic.pdf
6. Connor, J. et al. (2015). The burden of disease and injury attributable to alcohol in New Zealanders under 80 years of age: marked disparities by ethnicity and sex. New Zealand Medical Journal. 128(1409). Accessed November 2016. https://www.nzma.org.nz/journal/read-the-journal/all-issues/2010-2019/2015/vol-128-no-1409/6435
7. Hepatitis Foundation of New Zealand. (ND). Hepatitis C: Important information and statistics. Accessed November 2016. http://www.hepatitisfoundation.org.nz/files/8513/5059/9674/HCV_Information.pdf
8. Hepatitis Foundation of New Zealand. (2016). Accessed November 2016. http://www.hepatitisfoundation.org.nz/
9. NICE (2016b). Cirrhosis in over 16s: assessment and management. Accessed November 2016. www.nice.org.uk/guidance/ng50
10. Gissen, P. & Arias, I. (2015). Structural and functional hepatocyte polarity and liver disease. Journal of Hepatology. 63(4): 1023-1037.
11. Jenne, C. & Kubes, P. (2013). Immune surveillance by the liver. Nature Immunology. 14(10): 996-1006.
12. Yin, C. et al. (2013). Hepatic stellate cells in liver development, regeneration and cancer. Journal of Clinical Investigation. 123(5): 1902-1910.
13. Mehta, G. et al. (2014). Inflammation and portal hypertension—the undiscovered country. Journal of Hepatology. 61(1): 155-163.
14. Sendensky, A. & Dufour, J-F. (2011). Liver physiology. In Gines, P. et al. eds. Clinical gastroenterology: Chronic liver failure. Springer Science.
15. Pauli-Magnus, C., Meier, P. & Stieger, B. (2010). Genetic determinants of drug-induced cholestasis and intrahepatic cholestasis of pregnancy. Seminars in Liver Disease. 30(2): 147-159.
16. Hall, P. & Cash, J. (2012). What is the real function of the liver ‘function’ tests? Ulster Medical Journal. 81(1): 30-36.
17. Coates, P. (2011). Liver function tests. Australian Family Physician. 40(3): 113-115.
18. Zetterman, R. (2009). Evaluating the patient with abnormal liver tests. Accessed November 2016. http://www.medscape.com/viewarticle/710045_1
19. Weiskirchen, R. & Tacke, F. (2016). Liver fibrosis: which mechanisms matter? Clinical Liver Disease. 8(4): 94-99.
20. Mormone, E., George, J. & Nieto, N. (2011) Molecular pathogenesis of hepatic fibrosis and current therapeutic approaches. Chemico-biological Interactions.193(3): 225-231.
21. Wolf, D. (2015). Cirrhosis. Medscape Drugs and Diseases. Accessed November 2016. http://emedicine.medscape.com/article/185856-overview#a2
22. Carale, J., Azer, S. & Mekaroonkamol, P. (2015). Portal hypertension. Medscape Drugs and Diseases. Accessed November 2016. http://emedicine.medscape.com/article/182098-overview#a6
23. Bassari, R. & Koea, J. (2015). Jaundice and associated pruritis: A review of pathophysiology and treatment. World Journal of Gastroenterology. 21(15): 1404-1413.
24. Vilstrup, H. et al., (2014). Hepatic encephalopathy in chronic liver disease: 2014 practice guidelines by AASLD and EASL. American Association for the Study of Liver Diseases. Accessed November 2016. https://www.aasld.org/sites/default/files/guideline_documents/hepaticencephenhanced.pdf
25. Bernardi, M., Maggioli, C. & Zaccherini, G. (2012). Human albumin in the management of complications of liver cirrhosis. Critical Care. 16(2): 211.
26. Cicalere, L. (2015). Hepatocellular carcinoma. Medscape drugs and diseases. Accessed November 2016. http://emedicine.medscape.com/article/197319-overview#a4
27. Buggs, A. (2014). Viral Hepatitis. Medscape Drugs and Diseases.  Accessed November 2016. http://emedicine.medscape.com/article/775507-overview#a3
28. WHO. (2016). Hepatitis E Factsheet. Accessed November 216. http://www.who.int/mediacentre/factsheets/fs280/en/
29. Sood, G. et al. (2016). Acute liver failure. Medscape Drugs and Diseases. Accessed November 2016. http://emedicine.medscape.com/article/177354-overview?pa=zZUej7krLKTZjj1lD8%2FkSzJoDLe6ICHm3DaRuLIEl%2FO0fdPth65m7AU89ncpBoIdX8MwC0EECwzp432Skuf9qw%3D%3D#a1
30. Bernal, W. & Wendon, J. (2013). Acute liver failure. New England Journal of Medicine. 369: 2525-2534.